Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka(National Institute of Standards and Technology), Tony Mok(Chinese University of Hong Kong), Georgina Speake(Chinese University of Hong Kong), Ka‐Fai To(Chinese University of Hong Kong), James Chih‐Hsin Yang(National Taiwan University Hospital), Patrapim Sunpaweravong(Prince of Songkla University), Haiyi Jiang(AstraZeneca (Japan)), Emma Duffield(AstraZeneca (United Kingdom)), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Swan-Swan Leong(Chinese University of Hong Kong), Virote Sriuranpong(Chinese University of Hong Kong), Da-Tong Chu(Chinese Academy of Medical Sciences & Peking Union Medical College), Tsu-Yi Chao(Ministry of Health and Welfare), Nagahiro Saijo(National Cancer Center Hospital East), Sumitra Thongprasert(Chiang Mai University), Alison Armour(AstraZeneca (United Kingdom)), Yuri Rukazenkov(Chinese University of Hong Kong)
Cited by 1,604
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k